Introduction
Intratympanic (IT) administration of steroids has been shown to be an eff ective adjunct in the medical treatment of various inner ear disorders. Th e method of administration, dosage of steroids, and frequency of administration diff er among authors. Some otologists/neurotologists advocate placing a ventilating tube to facilitate repeated steroid administrations, and others perform repeated transtympanic injections using small-gauge needles under local anesthesia. Complications, although rare, include persistent tympanic membrane (TM) perforation, chronic otitis media, and dysgeusia. 1 Th e current study is a retrospective review of 11 cases involving patients treated by the senior author (R.T.S.) with IT dexamethasone administered at home through myringotomy tubes. Th e incidence of perforation in these patients is compared with the incidence of perforation in a control population of 50 patients who underwent myringotomy and tube placement without IT steroids.
Patients and methods
Eleven patients with sensorineural hearing loss (SNHL) and/or autoimmune ear disease (AIED) were treated through myringotomy tubes (19 ears) with one or several doses of IT dexamethasone, administered at home (table). All 11 patients had SNHL, 8 patients had AIED, and 1 patient had SSNHL. Prior to treatment, 7 patients complained of tinnitus, 5 experienced vertigo, 6 complained of aural fullness, 3 experienced fl uctuation of hearing, and 2 complained of nonspecifi c disequilibrium.
Dosages and duration of treatment. Dexamethasone 10 mg/ml was used in 7 patients and 4 mg/ml was used in 4 patients. No specifi c clinical guidelines determined the choice of concentration. Injectable dexamethasone was prescribed and instilled in the ears with a dropper. Th e patient was positioned so that the round window membrane would be bathed in this solution, and he or she was instructed to lie with the ear up for 15 minutes. Th e drops were given daily, 2 to 3 times/week, weekly, or biweekly depending on the patient's response as determined by audiogram and/or subjective improvement in tinnitus, hearing, or balance. Treatment continued for a minimum of 3 months, and longer in patients whose conditions worsened if dexamethasone instillation frequency was decreased or if the drops were stopped. Duration of treatment ranged from 5 months to >36 months. Patients were retreated as needed on the basis of symptoms and audiometric fi ndings.
Control group. Tympanic membrane perforation data for the 11 study patients were compared with those for a control group of 50 consecutive patients who had undergone myringotomy with tube insertion for middle ear dysfunction and who had not received steroid drops except as combined with antibiotic drops during the week following the surgical procedure.
Results
Eleven patients (19 ears) with SNHL and/or AIED (5 men, 6 women; age range: 35 to 80 years) were treated with IT dexamethasone (table) via self-administration at home. Th e time between development of otologic complaints and IT dexamethasone treatment ranged from 5 months to 8 years and 3 months. Prior to the administration of IT dexamethasone, all patients had been treated with other medications. All 11 had been treated with courses (oft en multiple) of oral prednisone.
Before undergoing IT steroid treatment, 10 of the patients had also received cytotoxic medications. Four patients had been treated with MTX and cyclophosphamide followed by infl iximab (table) . Oral steroids were discontinued once IT administration of dexamethasone began.
Th ree patients experienced TM perforations aft er IT dexamethasone therapy. No diff erence in the perforation rate was seen between patients who received 10 mg/ml of dexamethasone and those who received 4 mg/ml. One patient experienced a perforation 19 months aft er the beginning of IT therapy through a myringotomy tube. He developed a 25% stable left posteroinferior perforation that was apparent when the tube extruded spontaneously. He has not undergone tympanoplasty because he continued to require IT steroid drops, which are delivered three times weekly through the perforation.
In the second patient who developed a TM perforation, it was noted aft er 27 months of IT therapy following myringotomy. She had bilateral myringotomy tubes placed; 14 months later, she developed left otitis. She was treated with antibiotics, and the tube was removed from her ear canal. She received a new myringotomy tube aft er the infection resolved. Eleven months later, she experienced a left TM perforation, and then a right TM perforation. She subsequently underwent successful bilateral tympanoplasties aft er dexamethasone drops were discontinued, and her hearing and symptoms stabilized.
Th e third patient with a TM perforation had received IT dexamethasone injections through myringotomy tubes for about 7 months. During that time, he experienced persistent otitis media and otitis externa of the left ear, with a plugged myringotomy tube that was subsequently removed. Th e patient's left ear continued to have purulent drainage, and it was treated with antibiotic drops. He had developed moderate scarring in the left middle ear space from the infl ammatory response secondary to the ear infections. A central perforation of the left tympanic membrane was apparent on examination. Th e infection resolved aft er oral and topical treatment, but he continued to have a persistent posterior TM perforation of 30 to 40% in the area where the myringotomy tube was located. Since his ear was dry, IT dexamethasone therapy was resumed.
In this population of 11 patients, the incidence of TM perforation aft er IT steroids was 16% (3 of 19 ears). No perforations were reported in the control group.
Discussion
IT steroid delivery was fi rst proposed by Sakata in 1987, and in 1991 this treatment method was described by Itoh and Sakata, who reported using IT dexamethasone in 61 patients with unilateral Ménière disease. 2 Th ese patients suff ered from vertigo and other symptoms unresponsive to standard medical therapy. Th ey received four or fi ve weekly, 2-mg, IT dexamethasone injections to the aff ected ear. Th is technique resulted in relief of vertigo in 78% of patients and resolution or improvement of tinnitus in 74%. None of Itoh and Sakata's patients reported any deleterious side eff ects from the therapy. Th ese authors also pointed out that no basic studies had been performed explaining the mechanism of action of this new therapy. 2 IT steroid injection has become a common therapeutic option for sudden or rapidly progressive SNHL. Protocols vary and include placing ventilation tubes for repeat injections (with or without a MicroWick), placing round window catheters, or administering repeat transtympanic injections. Perforation of the TM is described as a rare complication, especially when steroid administration is performed with repeated injections. In fact, some investigators have not found any TM complications. 3, 4 Persistent perforations are noticed more oft en with the use of ventilation tubes. Barrs et al reported that 1 of 21 patients experienced persistent perforation. 5 Th is patient had a ventilation tube placed and was injected on a monthly basis for several months.
Kakehata et al reported that 2 of 6 diabetic patients with persistent perforation had been injected through a ventilation tube. 6 Herr and Marzo reported that 3 of 17 patients developed persistent perforations, one of whom developed chronic otitis media necessitating mastoidectomy. 1 Th ey had used a round window catheter in all patients. Ten patients had a MicroWick placed through a ventilating tube for an average of 13 days before myringoplasty and placement of the catheter. Th ey did not state whether the perforations were in patients with or without tubes.
Both patients in a report by Shapira et al had received radiation therapy with the ear in the irradiated fi eld. 7 Th ey had no other medical problems in their history that could have led to impaired wound healing. Th e authors postulated that the total or near-total breakdown observed was caused by the healing impairment associated with the steroids injected into the ear. 7 Steroid administration is used widely to treat SSNHL, either alone or in combination with other medications, 8 and for autoimmune inner ear disease. However, the prolonged use of high-dose systemic steroids has signifi cant side eff ects. Th e optimal dose and treatment duration are unknown and, therefore, oft en empirical and imprecise. Th e therapeutic eff ect of systemic steroids may not be ideal at nontoxic doses because of their limited ability to penetrate the blood-perilymph barrier. Th e IT route of administration has two theoretical advantages. First, there is potential for direct steroid uptake through the round window membrane, resulting in higher perilymph levels. [9] [10] [11] Th is was shown in several studies using guinea pigs as the model. Second, it is theorized that this route of administration minimizes systemic steroid absorption and toxicity.
Clinical studies of IT dexamethasone are sparse; the treatment is primarily used for patients with Ménière disease and not SSNHL. Silverstein et al observed that 41% of 46 patients treated with IT steroids for 1 month had improved hearing. 12 Sixty percent of these patients had Ménière disease. Itoh and Sakata observed substantial to complete control of vertigo spells in about 80% of 180 patients with refractory vertigo who were given IT dexamethasone. 2 Blakley's review of the clinical literature regarding IT therapy concluded that the use of IT steroids should remain investigational until more favorable data are available. 13 In 2007, a meta-analysis study concluded that there is no diff erence between systemic steroids and "other active treatment. " 14 Two recent studies showed diff erent outcomes of IT steroids. 15, 16 Th e fi rst was a prospective, open-label study by Ahn et al that compared systemic steroids and IT steroids plus systemic steroids and showed 73% and 70% recovery, respectively. 15 Th e authors concluded that there is no benefi t from adding IT steroids. Th e second study, which was a multicenter, double-blind, placebo-controlled, and randomized, study by Battaglia et al, was designed to compare hearing recovery from three treatment groups: high-dose systemic steroids and IT dexamethasone, systemic placebo and IT steroids, and systemic steroids and placebo IT injections (isotonic saline). 16 Th e authors concluded that the patients treated with combination therapy had a higher likelihood of recovery than patients given systemic steroids only (p < 0.5).
In another study, Ahn et al reported that IT steroids salvaged hearing in about 40% of patients when given within 1 to 2 weeks aft er failure of systemic steroids. 17 Th is study showed a declining rate of recovery when IT steroids were delayed; 30% aft er 1 month and 15% aft er 2 months. Th ree other studies showed benefi t from IT steroids aft er failure of systemic steroids. [18] [19] [20] Immune-mediated inner ear disease is similar to Ménière disease but has a more rapid course aff ecting both ears. 21 Recent data support an ionic imbalance of the endolymph as the fi nal common pathway in steroidresponsive autoimmune mouse hearing loss, suggesting that steroids improve and restore normal stria vascularis function. 22 Dexamethasone was shown to increase the expression of active and passive Na/K channels 23 and of aquaporins 24, 25 in the endolymph surrounding tissues.
Studies of cochlear gene expression have been conducted following two delivery methods. Hamid and Trune's data show that dexamethasone delivered systemically suppresses some proinfl ammatory cytokine genes in cochlear tissues, but a greater number of genes are down-regulated if the drug is delivered intratympanically. 26 Th us, the clinical observations of improved hearing recovery with IT steroids appear to be supported by animal studies. An added advantage is that systemic side eff ects from oral steroids are virtually eliminated. 27 Serious complications are rarely seen with IT therapy, although each method of delivery has the potential for complications. Persistent TM perforations can occur with therapy, particularly in patients treated with dexamethasone infusion. In fact, this problem prompted Jackson et al to change their dexamethasone concentra- tion from 24 mg/ml to 4 mg/ml in hopes of reducing the negative eff ect of steroids on healing, in particular on tympanostomy sites. 28 Th ese perforations were usually repaired in the offi ce by fat myringoplasty.
Glucocorticoid eff ects on healing are multifactorial and are related to the decreased intensity of the infl ammatory reaction. Th e concentration of several growth factors-keratinocyte growth factor, basic fibroblast growth factor, and transforming growth factor alpha-is decreased aft er the administration of systemic dexamethasone. 29, 30 Dexamethasone has been shown to inhibit collagen VII production via direct gene inhibition (COL7A1). 29 Dexamethasone is 25 to 80 times more potent than hydrocortisone as a glucocorticoid. Th e glucocorticoid potency of a 0.1% dexamethasone solution is equal to or greater than the potency of a 2% hydrocortisone solution. Spandow and Hellström 31 and Spandow et al 32 demonstrated that 2% hydrocortisone placed on perforated TMs for 10 days markedly slowed healing time. Th ey found that 50% of perforations were present up to 2 months postoperatively.
Doyle et al retrospectively reviewed cases in which patients had received IT steroid treatment, and uncontrolled, prospective cohort studies from 1996 to 2003, including patients with Ménière disease and sensorineural hearing loss. 33 Th ey reported no permanent TM perforations despite myringotomy for endoscopy and ventilation tube insertion. In a study by Kopke et al, acute otitis media occurred in 2 of 1,466 ears injected for tinnitus. 34 Silverstein et al treated 46 patients with Ménière disease via several IT delivery methods. 12 A Merocel wick was used in 19 patients. Th e permanent perforation rate was not reported, but they reported that "perforations of the TM appeared to heal slowly. " Sennaroglu et al reported otitis media in only 1 of 24 patients receiving IT dexamethasone, and 1 TM perforation that persisted for 1 month but closed with a paper patch. 35 In conclusion, chemical perfusion therapy of inner ear disease is generally safe and easy to perform. High inner ear medication concentrations can be achieved while minimizing systemic side eff ects. Most delivery methods are minimally invasive and can be performed in the offi ce. Patients can continue to self-administer medication in the ear at home through myringotomy tubes, titrating the frequency of administration to the individual's response. When perforations occur, they provide a convenient route for steroid instillation; and tympanoplasty appears eff ective aft er steroid therapy has been discontinued. Further prospective, randomized, controlled studies to evaluate the eff ects and complica-tions of IT perfusion of steroids for AIED and SNHL are warranted, and patients should be advised of the risk of persistent perforation when steroids are instilled through myringotomy tubes.
